Synaptogenix, Inc.: insider trades · United States · SEC (Form 4)

About Synaptogenix, Inc.

Synaptogenix, Inc. (NASDAQ: SNPX) is a United States-based biotechnology company listed on the NASDAQ market, and it is best understood as a highly focused micro-cap developer rather than a commercial-stage pharmaceutical platform. The company traces its origins to 2012, when it was formed as Neurotrope Bioscience, Inc.; it later became Synaptogenix through a legal and structural separation from Neurotrope that was completed in December 2020. Its corporate headquarters and operating base are in New York, New York, United States. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1571934/000141057825000518/snpx-20241231x10k.htm?utm_source=openai)) Synaptogenix’s core strategy centers on Bryostatin-1, a naturally derived molecule that has been studied primarily for Alzheimer’s disease and remains in the clinical testing stage. Management has also evaluated Bryostatin-1 in other neurodegenerative or cognition-related indications, including fragile X syndrome, multiple sclerosis, and Niemann-Pick type C disease. From an analyst perspective, that makes the company a single-asset or near-single-asset biotech with limited diversification and a valuation profile that is heavily dependent on scientific progress, clinical readouts, regulatory milestones, and access to capital. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1571934/000141057825000518/snpx-20241231x10k.htm?utm_source=openai)) In competitive terms, Synaptogenix operates in one of the most crowded and scientifically challenging therapeutic areas in global biotech: neurodegeneration, especially Alzheimer’s disease. Its edge is not scale, revenue breadth, or commercial infrastructure; rather, it lies in its differentiated scientific angle around Bryostatin-1 and the body of preclinical and clinical work built over time. The company has disclosed a material transfer agreement with the U.S. National Cancer Institute to source bryostatin for research and clinical trials, which is an important operational detail for a development-stage company with no large manufacturing footprint. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1571934/000141057825000518/snpx-20241231x10k.htm?utm_source=openai)) Recent corporate activity underscores the company’s financing-driven profile. In 2025, Synaptogenix completed a private funding round of $5.5 million through the sale of equity securities and warrants, highlighting the ongoing need for external capital that is typical for early-stage biotech firms. For investors monitoring SEC Form 4 insider transactions, that backdrop matters: insider buying or selling can be meaningful for sentiment, but it should be interpreted against the company’s clinical-risk and financing-risk framework. Overall, Synaptogenix remains a speculative NASDAQ-listed biotech in the United States, with its equity story tied to pipeline execution rather than current commercial revenues. ([stocktitan.net](https://www.stocktitan.net/sec-filings/SNPX/d-synaptogenix-inc-sec-filing-882489c88204.html?utm_source=openai))